PubMed日本語 - 癌の特別手当の医学腫瘍学者の認知は、気にかける。―QLifePro医療翻訳医療翻訳 QLifePro



Medical Oncologists' Perceptions of Financial Incentives in Cancer Care.

Published date 2012 Dec 26

Medical Oncologists' Perceptions of Financial Incentives in Cancer Care.


Published date



J Clin Oncol. 2012;


Jennifer L Malin, Jane C Weeks, Arnold L Potosky, Mark C Hornbrook, Nancy L Keating


Jennifer L. Malin, Jonsson Comprehensive Cancer Center and David Geffen School of Medicine at University of California at Los Angeles and Greater Los Angeles VA Healthcare System, Los Angeles, CA; Jane C. Weeks, Dana-Farber Cancer Institute; Nancy L. Keating, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Arnold L. Potosky, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; and Mark C. Hornbrook, Center for Health Research, Kaiser Permanente Northwest, Portland, OR.


PURPOSEThe cost of cancer care continues to increase at an unprecedented rate. Concerns have been raised about financial incentives associated with the chemotherapy concession in oncology practices and their impact on treatment recommendations. METHODSThe objective of this study was to measure the physician-reported effects of prescribing chemotherapy or growth factors or making referrals to other cancer specialists, hospice, or hospital admissions on medical oncologists' income. US medical oncologists involved in the care of a population-based cohort of patients with lung or colorectal cancer from the Cancer Care Outcomes Research and Surveillance (CanCORS) study were surveyed regarding their perceptions of the impact of prescribing practices or referrals on their income.ResultsAlthough most oncologists reported that their incomes would be unaffected, compared with salaried oncologists, physicians in fee-for-service practice, and those paid a salary with productivity incentives were more likely to report that their income would increase from administering chemotherapy (odds ratios [ORs], 7.05 and 7.52, respectively; both P < .001) or administering growth factors (ORs, 5.60 and 6.03, respectively; both P < .001). CONCLUSIONA substantial proportion of oncologists who are not paid a fixed salary report that their incomes increase when they administer chemotherapy and growth factors. Further research is needed to understand the impact of these financial incentives on both the quality and cost of care.


米国の医学腫瘍学者は、含んだCancer Care Outcomes Researchと検査が大部分の腫瘍学者が報告したそれらのincome.ResultsAlthoughの上で診療所または照会を処方して影響のそれらの認知に関して調査を受けたSurveillance(CanCORS)からの肺または結腸直腸癌にかかった人口に基づいた患者コホート保護下のそれらの収入が影響を受けない、給料の支払いを受ける腫瘍学者と比較して、診療報酬制の医師が、実行する、そして、生産性誘因で給料を支払われる人々が、よりそれらの収入が化学療法を行うことから増加すると報告しそうだった(それぞれオッズ比[ORs]、7.05と7.52;両方のP < .001)または成長因子を投与すること(それぞれORs、5.60と6.03;両方のP < .001)。

460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳